What side effects can Flecainide have?
Below you will find the most important information about possible, known side effects of Flecainide.
These side effects do not occur, but you can. Because every person reacts differently to medication. Please also note that the type and frequency of side effects may vary depending on the drug formulation (eg tablet, syringe, ointment).
Very Common Side Effects:
Dizziness (transient), drowsiness (transient), drowsiness (transient), blurred vision (blurred vision, vision loss), difficulty breathing.
Common side effects:
arrhythmia, gastrointestinal disturbances, depression, anxiety, sleep disorders, nervous disorders, gait insecurity, movement disorders, sensory disturbances, increased sweating, fainting, tinnitus, trembling, dizziness, flushing, drowsiness, nausea and vomiting , Constipation, abdominal pain, refusal to eat, diarrhea, indigestion, headache, weakness, fatigue, fever, water retention in the tissues, general malaise.
Occasional side effects:
White blood cell deficiency, red blood cell deficiency, confusion, delusions, memory loss, nerve disorders in arms and legs, cramps, pneumonia, flatulence, bloating, allergic reactions (skin rash, hair loss, nettle rash). !!!
Rare side effects:
Liver elevations (disappear after treatment).
Very rare and isolated side effects:
Rise of special antibodies in the blood (antinuclear antibodies).
What interactions does Flecainide show?
Please note that the interactions may vary depending on the drug formulation of a drug (eg tablet, syringe, ointment).
Interactions may occur from flecainide with cardiac glycosides and other agents that attenuate the cardiac excitation system. Here a mutual reinforcement of the effect is possible.
The increase in flecainide blood concentration is due to the concomitant use of cimetidine (gastric acid blocker), especially if renal performance is impaired. Also increase the blood concentration of flecainide paroxetine, fluoxetine and some other antidepressants, quinine and halofantrine (for malaria), the antiarrhythmic drug quinidine, the AIDS agents ritonavir, lopinavir and indinavir, dehydrating agents of the drug groups thiazides and loop diuretics
(for example, bumetanide), the antifungal agent terbinafine and the roughening agent bupropion.
The H1 antihistamines astemizole and terfenadine (for allergy) increase the risk of cardiac arrhythmias.
When concomitant with flecainide and digoxin (an agent that improves cardiac output), the digoxin concentration in the blood may rise by about 15 to 25 percent.
If flecainide is taken in combination with the antiarrhythmic drugs disopyramide or amiodarone or the beta-blocker propranolol, the blood concentrations of the active substances may mutually increase, which increases the risk of dangerous side effects.
Decreasing cardiac output with concomitant use of flecainide must be expected for calcium channel blockers of the verapamil type and beta-blockers (used primarily to treat heart disease).
Antiepileptic drugs such as phenytoin, phenobarbital and carbamazepine can speed up the breakdown of flecainide in the liver and reduce its effects.
Co-administration of activated charcoal should only be carried out after consultation with the doctor, since in these cases the uptake of flecainide from the intestine into the bloodstream (absorption) and thus the efficacy of flecainide may be reduced.